27 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs … which units of account of the collaboration are deemed to be within the scope of ASC 808 and those that are reflective of a vendor-customer relationship
6-K
EX-99.1
OBSVF
ObsEva SA
25 Apr 22
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH
7:00am
(CCO), is purpose-built to accelerate customer performance to address modern market realities. Syneos Health brings together approximately 27,000
6-K/A
EX-99.1
fr4w6dda63crhkil
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K
EX-99.1
zquzz2dltvwv
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
424B5
cg47gf 8z6s4qm
5 Mar 21
Prospectus supplement for primary offering
7:55am
6-K
EX-1.1
fvau07otad7two
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
424B5
93lghu7khk4by
8 Sep 20
Prospectus supplement for primary offering
7:31am
F-3
gm3 2i3u74v23p
7 Aug 19
Shelf registration (foreign)
8:24am
424B5
q616rndz
7 Aug 19
Prospectus supplement for primary offering
8:18am
6-K
EX-99.1
xnacvjf4t
7 Aug 19
Current report (foreign)
7:21am
6-K
EX-1.1
fkjlpqhmj ldyqn
22 Jun 18
ObsEva Announces Launch of ProposedFollow-on Public Offering
4:06pm
424B5
cqkt3
20 Jun 18
Prospectus supplement for primary offering
5:32pm